CVS GroupLSE:CVSG +0.68%89 EBITDA Margin % is 15.21% as of Dec. 2025, which is 2% below its 10-year median of 15.59. GuruFocus rates LSE:CVSG with a GF Score™ of 89/100 and a GF Value™ of £13.43 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, CVS Group ranks better than 64.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CVS Group's EBITDA for the
six
months ended in Dec. 2025 was £54.3 Mil. CVS Group's Revenue for the
six
months ended in Dec. 2025 was £356.9 Mil. Therefore, CVS Group's EBITDA margin for the quarter that ended in Dec. 2025 was 15.21%.
CVS Group (LSE:CVSG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CVS Group EBITDA Margin % Related Terms
CVS Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CVS Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CVSG vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, CVS Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CVS Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CVS Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Group (LSE:CVSG) has a EBITDA Margin % of 15.21% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CVS Group and its competitors. This is near median its historical median of 15.59. Over the past decade, CVS Group's EBITDA Margin % has ranged from 11.44 to 20.00. According to the industry distribution chart, CVS Group ranks #234 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 35%.
Is CVS Group's EBITDA Margin % too high?
CVS Group's current EBITDA Margin % of 15.21% is near median its 10-year median of 15.59. Over the past 10 years, this metric has ranged from a low of 11.44 to a high of 20.00. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. CVS Group's value of 15.21% is 49% above this industry median. Based on the distribution chart, CVS Group ranks #234 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, CVS Group has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CVS Group's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CVS Group ranks #234 out of 668 companies for EBITDA Margin %. This puts CVS Group in the upper half of its industry. The industry median EBITDA Margin % is 10.21. CVS Group's value of 15.21% is 49% above this benchmark. Historically, CVS Group's own EBITDA Margin % has ranged from 11.44 to 20.00 over the past decade. While the company's 10-year median is 15.59 vs. the industry median of 10.21, CVS Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Group's current EBITDA Margin % of 15.21% is 49% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CVS Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Group's current EBITDA Margin % is 15.21%, which is near median its own 10-year median of 15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Group stock overvalued right now?
Based on GuruFocus' analysis, CVS Group (LSE:CVSG) is currently considered Modestly Undervalued. The stock's GF Value™ is £13.43, compared to a current price of £11.81 — trading 12.1% below its estimated fair value. The current EBITDA Margin % is 15.21%, which is near median its 10-year median of 15.59 and 49% above the Healthcare Providers & Services industry median of 10.21. CVS Group's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CVS Group (LSE:CVSG), the current EBITDA Margin % is 15.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Group (LSE:CVSG) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Group stock appears to be undervalued.
The current stock price of £11.81 is trading 12.1% below its estimated GF Value™ of £13.43.
GuruFocus considers CVS Group to be Modestly Undervalued.
Key valuation signals for LSE:CVSG:
EBITDA Margin %: 15.21% (near median its 10-year median of 15.59)
GF Value™: £13.43 vs. price of £11.81 (12.1% below fair value)
Industry Position: 49% above the Healthcare Providers & Services median (#234 of 668)
No single metric tells the full story. See the LSE:CVSG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Group PLC is a veterinary service provider in the United Kingdom. The group operates through three business divisions: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. The veterinary practice segment generates the majority of the revenues. The company facilitates its veterinary services through its diagnostics, laboratory reports, and pet cremation services. It also offers retail pharmacy through Animed Direct. Geographically, it generates the majority of its revenue from the United Kingdom and also operates in Australia.
89GF Score
Get the complete analysis for LSE:CVSG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CVSG has been successfully added to your 
